Eukaryotic expression vectors resistant to transgene silencing

Inventors

Williams, James A.

Assignees

Aldevron LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9506082-B2

Patent

Publication Date

2016-11-29

Expiration Date


Abstract

The present invention relates to recombinant DNA molecules such as plasmids, non-viral vectors, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules in cell lines and organisms.

Core Innovation

The invention describes anti-silencing expression vectors in which tRNA promoters flank a eukaryotic expression cassette. The promoters contain RNA polymerase III type II promoter A-box and B-box elements and are stated to prevent gene silencing. The cassette places a transgene under the control of a heterologous promoter, and the claimed method improves the duration of transgene expression in target vertebrate cells.

The partial content identifies gene silencing as the problem addressed: it limits the duration of transgene expression. The described vectors use small tRNA promoter elements, particularly the human tRNA valine promoter sequence, to reduce silencing and extend expression compared with the same vector lacking the flanking promoters. The content presents these elements as an alternative to larger matrix attachment region inserts.

Claims Coverage

The three independent claims cover methods for improving transgene-expression duration using expression vectors with tRNA promoters flanking a eukaryotic expression cassette. Their inventive features concern the promoter elements and vector composition, an antibiotic-free selectable marker with a vector-backbone modification, and the specified human tRNA valine promoter sequence.

Flanking tRNA promoters for extended transgene expression

Claim 1 covers an expression vector with a prokaryotic replication origin, a selectable marker, and a eukaryotic expression cassette flanked upstream and downstream by tRNA promoters. Each promoter comprises RNA polymerase III type II promoter A-box and B-box elements and is stated to prevent gene silencing. The claimed expression duration exceeds that achieved with the same vector lacking the flanking promoters. Dependent claims specify the human tRNA valine promoter sequence of SEQ ID NO:2 and identify non-viral, viral, integrating, non-integrating, and plasmid vectors.

Antibiotic-free selectable marker in a flanked expression vector

Claim 4 specifies an antibiotic-free selectable marker in the expression vector, alongside a eukaryotic expression cassette flanked by tRNA promoters containing RNA polymerase III type II promoter A-box and B-box elements. The vector-backbone modification is [procedural detail omitted for safety]. The claimed expression duration exceeds that achieved with the same vector lacking the flanking promoters. Dependent claims specify vector categories and the human tRNA valine promoter sequence.

Human tRNA valine promoters for extended transgene expression

Claim 7 specifies an antibiotic-free selectable marker and tRNA promoters comprising the human tRNA valine promoter nucleic acid sequence identified as SEQ NO:2, flanking a eukaryotic expression cassette. The promoters are stated to prevent gene silencing, and the claimed expression duration exceeds that achieved with the same vector lacking the flanking promoters.

Together, the independent claims cover flanking tRNA promoters as anti-silencing elements for extending transgene-expression duration, with claims 4 and 7 specifying an antibiotic-free selectable marker and claim 7 specifying the human tRNA valine promoter sequence.

Stated Advantages

The tRNA promoters prevent gene silencing and provide a greater duration of transgene expression than the same vector without the upstream and downstream promoters.

The partial content presents the small tRNA promoter elements as an alternative to larger matrix attachment region inserts.

Documented Applications

The claimed vectors are used to express a transgene in target vertebrate cells or in a vertebrate organism comprising target vertebrate cells. The partial content reports expression studies in CHO and HEK293 cells.

The partial content depicts proposed placement of the anti-silencing elements in retroviral vectors.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.